Alexion Pharmaceuticals AAQS 2024
Alexion Pharmaceuticals AAQS
Ticker
ISIN
WKN
Alexion Pharmaceuticals har en aktuel AAQS på 0. En høj AAQS kan betragtes som et positivt tegn på, at virksomheden udvikler sig succesfuldt. Investorerne kan forvente, at virksomheden er på rette spor mod at skabe overskud. På den anden side er det vigtigt at betragte AAQS for aktien Alexion Pharmaceuticals i forhold til de opnåede overskud og sammenligne med andre virksomheder i samme branche. En høj AAQS er ikke en absolut garanti for en positiv fremtid. Det er kun på den måde, man kan få et komplet billede af virksomhedens præstationer. For bedre at kunne vurdere virksomhedens udvikling er det vigtigt at betragte AAQS i sammenligning med andre virksomheder i samme branche. Generelt bør investorer altid betragte en virksomheds AAQS i sammenhæng med andre nøgletal som overskud, EBIT, cash flow og andre for at træffe en velbaseret investeringsbeslutning.
Alexion Pharmaceuticals Aktienanalyse
Hvad gør Alexion Pharmaceuticals?
Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Alexion Pharmaceuticals Omsætning efter segment
I årsrapporten for Alexion Pharmaceuticals-aktien (US0153511094, 899527, ALXN) opdeles omsætningen i 1 segmenter: 1. Therapies. Aktien Alexion Pharmaceuticals (WKN: 899527, ISIN: US0153511094, Ticker-Symbol: ALXN) er en førende investering for investorer, der er interesserede i en deltagelse i Health Care-sektoren.
100 % Therapies
Ofte stillede spørgsmål om Alexion Pharmaceuticals aktien
Alexion Pharmaceuticals aktien kan indgå i opsparingsplaner hos følgende udbydere: Trade Republic
Andere Kennzahlen von Alexion Pharmaceuticals
Vores aktieanalyse af Alexion Pharmaceuticals Omsætning-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Alexion Pharmaceuticals Omsætning. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser:
- Alexion Pharmaceuticals Omsætning
- Alexion Pharmaceuticals Overskud
- Alexion Pharmaceuticals P/E
- Alexion Pharmaceuticals KUV
- Alexion Pharmaceuticals EBIT
- Alexion Pharmaceuticals Udbytte
- Alexion Pharmaceuticals Aktier
- Alexion Pharmaceuticals Markedsværdi
- Alexion Pharmaceuticals Gæld
- Alexion Pharmaceuticals Forpligtelser
- Alexion Pharmaceuticals Egenkapital
- Alexion Pharmaceuticals AAQS
- Alexion Pharmaceuticals Medarbejdere
- Alexion Pharmaceuticals ROE
- Alexion Pharmaceuticals ROA
- Alexion Pharmaceuticals ROCE